 |
|||||
|
|||||
|
Confirmed title: Lean delivery of a sulfoximine-based inverse RORyt agonist for topical administration
|
|||||
|
19 June: 13:30 - 14:00
|
|||||
|
Dr Craig Harris, Scientific Advisor - API Synthesis & Chemical Development, Galderma
|
|||||
|
ABSTRACT
|
|||||
|
As part of a continuous improvement program at Galderma, we have been exploring ways to accelerate DMTA (Design-Make-Test-Analyse) cycle times and deliver our project milestones more rapidly from lead generation into early development. As the Make part invariably takes the most time, we have been intensely focusing our efforts on how to be more efficient and reactive in drug discovery synthesis through better de-risking our route design and frontloading the synthesis process by streamlining our reagent sourcing through our CROs partnerships. This presentation highlights the actions we put in place for our RORyt target and focuses on the evolution of our route design from our first linear medicinal chemistry route to the optimized racemic route used to deliver 100 g quantities of our lead sulfoximine-based RORyt inverse agonist in a near seamless transition.
|
|||||
|
BIOGRAPHY
|
|||||
|
Craig currently leads the discovery and development synthesis for Galderma, the pharmaceutical branch of Nestlé Skin Health, operating out of the offices of the Entre-Deux-Villes site, Switzerland. During his 6 years at Galderma, Craig drove both internal and external synthesis (CRO) teams to deliver 10 development candidates on a variety of targets linked to skin diseases such as psoriasis, acne, skin cancer, atopic dermatitis and in the aesthetic and corrective field on the Sophia Antipolis site in France. Prior to joining Galderma, Craig held a similar role at AstraZeneca, driving the synthesis for the Oncology iMed in Reims, France where he contributed to many discovery programs including 3 clinical candidates as well as to several continuous improvement projects.
|
|||||
|
COMPANY PROFILE
|
|||||
|
Galderma
|
|||||
|
Nestlé Skin Health is part of Nestlé's global business portfolio. Nestlé Skin Health aims to enhance the quality of people's lives by focusing on science-based solutions for skin health. Our products help protect, nourish and enhance, and - when needed - treat, correct and restore skin health. This holistic view of skin health, addressing both healthy and compromised skin, is fundamental to our mission.
To meet a broad range of skin health needs, we offer a range of leading medical and consumer skin health brands, through three business units: Prescription, Aesthetics (both under the Galderma brand), and Consumer care. Nestlé Skin Health focuses on innovation in 7 areas: Acne, rosacea, psoriasis, atopic dermatitis, skin aging, sun protection and skin cancer. |
Learn more about BOS2019
